Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial
第一作者机构:[1]Beijing Canc Hosp, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
Sun Yan,Hu Chaosu,Lin Qin,et al.Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial[J].JOURNAL OF CLINICAL ONCOLOGY.2022,40(16):
APA:
Sun, Yan,Hu, Chaosu,Lin, Qin,Gao, Li,Wang, Jianhua...&Pan, Jian-Ji.(2022).Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial.JOURNAL OF CLINICAL ONCOLOGY,40,(16)
MLA:
Sun, Yan,et al."Nimotuzumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with locally advanced nasopharyngeal carcinoma (NPC): A prospective, randomized-controlled, double-blinded, multicenter phase III clinical trial".JOURNAL OF CLINICAL ONCOLOGY 40..16(2022)